AKT1 and hepatocellular carcinoma: Using this approach, interleukin 7 (IL7) and mal, T cell differentiation protein 2 (MAL2) were identified as contributing to HCC-associated Sorafenib resistance by dysregulating the JAK/STAT and PI3K/AKT signaling pathways.